Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease
Alexis Bosman, Michael J. Edel, Gillian M. Blue, Rodney James Dilley, Richard Paul Harvey, David Scott Winlaw · Journal of Clinical Medicine · 2015
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Clinical Medicine · Multidisciplinary Digital Publishing Institute · review · 2015
Abstract
Congenital heart disease places a significant burden on the individual, family and community despite significant advances in our understanding of aetiology and treatment. Early research in ischaemic heart disease has paved the way for stem cell technology and bioengineering, which promises to improve both structural and functional aspects of disease. Stem cell therapy has demonstrated significant improvements in cardiac function in adults with ischaemic heart disease. This finding, together with promising case studies in the paediatric setting, demonstrates the potential for this treatment in congenital heart disease.
Furthermore, induced pluripotent stems cell technology, provides a unique opportunity to address aetiological, as well as therapeutic, aspects of disease.
Open the resolved locator · 10.3390/jcm4040768
Metadata licence: OpenAlex metadata (CC0)